Olga Oikonomidou
Clinical Translational Research in Breast Cancer
Research in a Nutshell
Dr Oikonomidou’s group is developing non-invasive analyses of breast cancer in order to understand better the breats cancer biology, identify potential therapeutic targets in cancer (early and advanced) and identify early a patient’s response to treatment.
People |
|
| Olga Oikonomidou | Senior Clinical Lecturer in Breast Cancer Medicine & Consultant Medical Oncologist Breast Cancer Translational Research Group Leader & Principal Investigator |
|
Natalie Wilson |
Tissue Consenter/Processor |
| Sana Shabbir | PhD student |
| Fiona Semple | Senior Post Doctoral Fellow |
Contact
Collaborations
- Department of Oncology-Pathology, Karolinska Institutet Breast Center, Karolinska University Hospital
- Institute of Biological Chemistry, Biophysics and Bioengineering, Nasmyth Building, Heriot-Watt University
- Centre of Cardiovascular Science, University of Edinburgh
Partners and Funders
- BCI grant (£100,000) September 2019 Co-PI: Genomics of Endocrine Therapy Resistance – Tailoring Treatment using Personalised Genomic Analysis
- Make2ndsCount (£190,000) June 2019 PI: Identification of biomarkers of response to CDK4/6 inhibitors in cfDNA sequential samples from patients with secondary breast cancer. November 2019
- CRUK Early Cancer Detection initiative (£475K) Co-Inv: ‘’ Multiplex methylation analysis of cell-free DNA for early cancer diagnosis. February 2018.
- NIHR National Institute for Health Research £781K (EME) Co-PI: “Cardiac CARE: A multicentre prospective randomised open-label blinded end-point controlled trial of cardiac troponin guided combination angiotensin receptor blockade and beta blocker therapy to prevent cardiac toxicity in anthracycline treated breast cancer patients”, 3.5 years from September 2017.
- Chief Scientist Office Research Grant (£220,883) Co-PI : Novel sample preparation for improved circulating tumour DNA analysis. 3 years from July 2015.
- MRC Confidence in Concept Scheme - Translation of Medical Informatics (£60,000) PI: Bioinformatics analysis of the NEO pilot study. 2 years from May 2014.
- CRUK Grant-Development Fund (£25,000) PI: for ‘’The NEO study: a study of factors predicting response to neoadjuvant chemotherapy in breast cancer patients’’. April 2014.
- University of Edinburgh Internal fund (£40,000) Co-PI: the role of Magnetic Resonance Phosphorous Spectroscopy (31P-MRS) in detecting changes in heart function associated with the use of chemotherapy drugs used to treat breast cancer. December 2014.
If you are interested to make a donation to translational breast cancer research please get in touch with
Leisa Thomas
Senior Philanthropy Officer, Health, Medicine and Veterinary Medicine
www.ed.ac.uk/development-alumni
Scientific Themes
Breast cancer, Translational studies, Genomics, Transcriptomics, cfDNA, DNA methylation, Personalised Medicine.
Technology Expertise
Trascriptomics, ddPCR, Sanger Sequencing.